{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood+sample%3A+Sub-study+group&page=2", "query": { "intervention": "Blood sample: Sub-study group", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood+sample%3A+Sub-study+group&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T15:35:40.500Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05463133", "title": "Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Granulomatous Disease" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Pheripheral blood stem cells", "type": "BIOLOGICAL" }, { "name": "Emapalumab-Izsg", "type": "DRUG" }, { "name": "Tociluzumab", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "4 Years to 65 Years" }, "enrollment_count": 50, "start_date": "2022-07-08", "completion_date": "2032-12-31", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-09-27T15:35:40.500Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05463133" }, { "nct_id": "NCT06183502", "title": "HIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Sexually Transmitted Infections", "Gay", "Pre Exposure Prophylaxis" ], "interventions": [ { "name": "Quantitative survey", "type": "BEHAVIORAL" }, { "name": "HIV and STI testing", "type": "PROCEDURE" }, { "name": "Qualitative Assessment", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL", "PROCEDURE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 675, "start_date": "2024-06-29", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-27T15:35:40.500Z", "location_count": 3, "location_summary": "San Diego, California • Atlanta, Georgia • Chicago, Illinois", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06183502" }, { "nct_id": "NCT01870986", "title": "Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-06410293", "type": "BIOLOGICAL" }, { "name": "Humira (adalimumab-EU)", "type": "BIOLOGICAL" }, { "name": "Humira (adalimumab-US)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 210, "start_date": "2013-05", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2014-02-14", "last_synced_at": "2026-09-27T15:35:40.500Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01870986" }, { "nct_id": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Previously Untreated Relapsed Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Samalizumab (BAML-16-001-S1)", "type": "BIOLOGICAL" }, { "name": "BI 836858 (BAML-16-001-S2)", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Daunorubicin (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S2)", "type": "DRUG" }, { "name": "AG-221 (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Daunorubicin (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Pevonedistat (BAML-16-001-S9)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S9)", "type": "DRUG" }, { "name": "AG-120 (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "AZD5153 (BAML-16-001-S10)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S10)", "type": "DRUG" }, { "name": "TP-0903 (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "AZD5991 (BAML-16-001-S18)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S18)", "type": "DRUG" }, { "name": "SNDX-5613 (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 1)", "type": "DRUG" }, { "name": "ficlatuzumab (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S24)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 2)", "type": "DRUG" }, { "name": "Bleximenib (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Revumenib (BAML-16-001-S26/HO177)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S26/HO177)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Beat AML, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3000, "start_date": "2016-11", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-27T15:35:40.500Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013998" }, { "nct_id": "NCT07622901", "title": "Fasting InTervention for Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Prolonged Overnight Fasting (POF)", "type": "BEHAVIORAL" }, { "name": "Blood Specimen Collection", "type": "PROCEDURE" }, { "name": "Blood Sugar Monitor", "type": "OTHER" }, { "name": "Hysterectomy", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "PROCEDURE", "OTHER" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2026-02-27", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-09-27T15:35:40.500Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07622901" }, { "nct_id": "NCT03930524", "title": "Adaptive Preventive Intervention for College Alcohol Use", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "College Student Drinking" ], "interventions": [ { "name": "Personalized Normative Feedback (PNF)", "type": "BEHAVIORAL" }, { "name": "Self-Monitoring (SM)", "type": "BEHAVIORAL" }, { "name": "Web-BASICS", "type": "BEHAVIORAL" }, { "name": "Health Promotion Consultation", "type": "BEHAVIORAL" }, { "name": "M-Bridge Online Health Coach", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "18 Years to 21 Years" }, "enrollment_count": 891, "start_date": "2019-07-31", "completion_date": "2022-08-01", "has_results": true, "last_update_posted_date": "2023-04-12", "last_synced_at": "2026-09-27T15:35:40.500Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03930524" }, { "nct_id": "NCT03956680", "title": "An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Cancers" ], "interventions": [ { "name": "BMS-986301", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2019-03-26", "completion_date": "2024-04-24", "has_results": false, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-09-27T15:35:40.500Z", "location_count": 4, "location_summary": "Chicago, Illinois • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03956680" }, { "nct_id": "NCT00147251", "title": "Stop Atherosclerosis in Native Diabetics Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cardiovascular Disease", "Hypertension", "Hyperlipidemia", "Diabetes", "Carotid Atherosclerosis" ], "interventions": [ { "name": "FDA approved drugs to treat blood pressure and cholesterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cynthia West", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 548, "start_date": "2003-05", "completion_date": "2007-05-01", "has_results": true, "last_update_posted_date": "2021-07-07", "last_synced_at": "2026-09-27T15:35:40.500Z", "location_count": 4, "location_summary": "Chinle, Arizona • Phoenix, Arizona • Lawton, Oklahoma + 1 more", "locations": [ { "city": "Chinle", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Lawton", "state": "Oklahoma" }, { "city": "Rapid City", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00147251" }, { "nct_id": "NCT07209527", "title": "Truway Diagnostic Tools in Primary Care", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Chronic Disease", "Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight", "Hypertension", "Cardiovascular Disease Acute", "Hyperlipidemia", "Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD", "Peripheral Artery Disease", "Metabolic Syndrome", "Prediabetes" ], "interventions": [ { "name": "Truway Portable Ultrasound Device", "type": "DEVICE" }, { "name": "Truway Blood Glucose Monitor", "type": "DEVICE" }, { "name": "Standard Oral Hypoglycemic Agent", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Truway Health, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 200, "start_date": "2025-10-01", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-09-27T15:35:40.500Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07209527" }, { "nct_id": "NCT03867461", "title": "The Effects of MAP and EtCO2 on Venous Sinus Pressures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Idiopathic Intracranial Hypertension" ], "interventions": [ { "name": "Venous Sinus Stenting", "type": "PROCEDURE" }, { "name": "Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range)", "type": "OTHER" }, { "name": "Adjustment to Mean Arterial Pressure (100-110 mmHg range)", "type": "OTHER" }, { "name": "Adjustment to Mean Arterial Pressure (60-80 mmHg range)", "type": "OTHER" }, { "name": "Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2019-06-20", "completion_date": "2019-09-25", "has_results": false, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-09-27T15:35:40.500Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03867461" } ] }